<DOC>
	<DOC>NCT01150162</DOC>
	<brief_summary>A Prospective Randomized, Multi-center study to assess the Safety and Efficacy of Mucosta (Rebamipide), in combination with Omeprazole as adjuvant therapy in Gastric Ulcer Patients.</brief_summary>
	<brief_title>Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Rebamipide</mesh_term>
	<criteria>Patients with dyspepsia or epigastric pain and endoscopically proven gastric and duodenal ulcers Required laboratory parameters and time limits (screening blood tests will be taken including hemoglobin, white blood cell count, random glucose, potassium, sodium, chlorine, creatinine, AST, ALT, bilirubin, and alkaline phosphatase) Age &gt; 18 years A statement that all patients must have signed an informed consent form prior to registration in study Patients who had undergone surgery for ulcers History of hypersensitivity to drugs to be used in the study Women who are pregnant or lactating or intended to get pregnant during the study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>